Frontlight ResearchEarly access
Lupus (SLE) trials in Spain
37 of 42 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Barcelona, Madrid, Santander
- Age
- 18 years to 75 years
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - Phase 1/2Taking peopleStudy to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis
- Where
- Badalona, León, Madrid, Murcia, Pamplona, Salamanca, Santiago de Compostela, Sevilla
- Age
- 18 years to 65 years
- People
- 10
- Run by
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07799116 · EU 2025-522449-23-00 - Phase 3Taking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Barcelona, Córdoba, Galdakao, Madrid, Sabadell, San Sebastián de los Reyes, Santander, Sevilla, Valencia
- Age
- 18 years and over
- People
- 113 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523670-17-00 - Phase 3Taking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Esplugues De Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia
- Age
- 5 years to 17 years
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - Phase 3Taking peopleLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Alcobendas, Madrid, Sabadell, Santiago de Compostela, Valladolid
- Age
- 18 years to 75 years
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00 - Phase 2Taking peopleTreatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
- Where
- Valladolid
- Age
- 18 years to 64 years
- People
- 20
- Run by
- Red de Terapia Celular
See details and how to joinNCT03673748 · EU 2024-514750-67-00 - Phase 1Taking peopleA Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
- Where
- Córdoba, Pamplona, Sevilla, Valencia
- Age
- 18 years and over
- People
- 51 worldwide
- Run by
- CRISPR Therapeutics AG
See details and how to join2024-518528-54-00 - Phase 3Not yet taking people in SpainA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Where
- Alcobendas, Barcelona, Bilbao, Girona, Madrid, Pamplona, Valencia
- Age
- 18 years to 75 years
- People
- 300 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT07201129 · EU 2025-522984-14-00 - Phase 1Taking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Barcelona, Madrid
- Age
- 18 years and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - Phase 1Taking peopleA study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus
- Where
- A Coruña, Sabadell
- Age
- 18 years and over
- People
- 11 worldwide
- Run by
- Climb Bio Inc.
See details and how to join2024-520385-57-01 - Phase 1Taking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Barcelona, Madrid, Majadahonda
- Age
- 18 years to 70 years
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - Phase 1Taking peopleA Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Where
- A Coruña, Sabadell
- Age
- 18 years to 65 years
- People
- 30 worldwide
- Run by
- Climb Bio, Inc.
See details and how to joinNCT07011043